Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023 II. Introduction: Difference between revisions

From GxPlex

Jump to: navigation, search
m 1 revision imported
m 1 revision imported
 
(9 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{#set:
{{ReferenceData
|HasDocument=Document:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023
|has_document=Document:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023
|RefScope=G
|module=3
|RefDocPart=II. Introduction
|unit=3.1.1
|RefLanguage=EN
|scope=G
|RefTagsEN=
|doc_part=II. Introduction
|RefTagsOriginal=
|language=EN
|RefTagsFR=
|entry_by=Florian Adragna
}}
|contributors=
 
|tags=TAG-00032-Inf-ngs ++ TAG-00029-Inf-rte ++ TAG-00149-Sig-nds ++ TAG-00030-Inf-onu
== Document Information ==
|tags_display=[[Glossary:TAG-00032-Inf-ngs|Consent process]], [[Glossary:TAG-00029-Inf-rte|Informed consent]], [[Glossary:TAG-00149-Sig-nds|Signature]], [[Glossary:TAG-00030-Inf-onu|Consent form]]
{{:Document:USA Informed Consent - FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023}}
|comment=Common misunderstanding of informed consent as a document
 
|content=II. SUMMARY OF THE CONSENT PROCESS
== Reference Details ==
{| class="wikitable" style="width:100%;"
|-
! scope="row" style="width:200px;" | Scope
| G
|-
! scope="row" style="width:200px;" | Document part
| II. Introduction
|-
! scope="row" style="width:200px;" | Language
| EN
|-
! scope="row" style="width:200px;" | Original entry by
| Florian Adragna
|-
! scope="row" style="width:200px;" | Contributors
|  
|-
! scope="row" style="width:200px;" | Tags (EN)
|  
|-
! scope="row" style="width:200px;" | Tags (original language)
|
|-
! scope="row" style="width:200px;" | Tags (FR)
|  
|-
! scope="row" | Comment
| Common misunderstanding of informed consent as a document
|}
 
== Text ==
II. SUMMARY OF THE CONSENT PROCESS
To many, the term informed consent is mistakenly viewed as synonymous with obtaining a subject’s signature on the consent form;9 however, obtaining documentation of a subject’s informed consent is only part of the consent process. Informed consent involves providing a prospective subject, or their legally authorized representative (LAR), with adequate information to allow for an informed decision about participation in the clinical investigation prior to enrollment. Informed consent also involves facilitating the prospective subject’s understanding of the information, providing adequate opportunity for the prospective subject to ask questions and to consider whether to participate, obtaining the prospective subject’s voluntary agreement to participate prior to enrollment, and continuing to provide information as the clinical investigation progresses or as the enrolled subject or situation requires.10
To many, the term informed consent is mistakenly viewed as synonymous with obtaining a subject’s signature on the consent form;9 however, obtaining documentation of a subject’s informed consent is only part of the consent process. Informed consent involves providing a prospective subject, or their legally authorized representative (LAR), with adequate information to allow for an informed decision about participation in the clinical investigation prior to enrollment. Informed consent also involves facilitating the prospective subject’s understanding of the information, providing adequate opportunity for the prospective subject to ask questions and to consider whether to participate, obtaining the prospective subject’s voluntary agreement to participate prior to enrollment, and continuing to provide information as the clinical investigation progresses or as the enrolled subject or situation requires.10
[...]
[...]
}}

Latest revision as of 13:49, 16 July 2026



Document information
Reference USA Informed Consent -

FDA Guidance for IRBs, Clinical Investigators, and Sponsors Aug-2023

Validity area USA
Scope(s) G
Document name Informed Consent -

FDA Guidance for IRBs, Clinical Investigators, and Sponsors

Version / Revision Aug-2023
Status Current
Document type Official recommendation
Language(s) EN
Description Informed Consent

Guidance for IRBs, Clinical Investigators, and Sponsors

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 3 — Unit 3.1.1
Scope G
Document part II. Introduction
Language EN
Original entry by Florian Adragna
Contributors
Tags Consent process, Informed consent, Signature, Consent form

Content

II. SUMMARY OF THE CONSENT PROCESS To many, the term informed consent is mistakenly viewed as synonymous with obtaining a subject’s signature on the consent form;9 however, obtaining documentation of a subject’s informed consent is only part of the consent process. Informed consent involves providing a prospective subject, or their legally authorized representative (LAR), with adequate information to allow for an informed decision about participation in the clinical investigation prior to enrollment. Informed consent also involves facilitating the prospective subject’s understanding of the information, providing adequate opportunity for the prospective subject to ask questions and to consider whether to participate, obtaining the prospective subject’s voluntary agreement to participate prior to enrollment, and continuing to provide information as the clinical investigation progresses or as the enrolled subject or situation requires.10 [...]